Abstract: Chronic kidney disease (CKD)and cardiovascular disease (CVD) are the major causes of death in patients with diabetes.The activation of renin-angiotensin-aldosterone system (RAAS) and natriuretic peptide (NP) system has attracted more and more attention in recent years.A dual-acting drug that simultaneously inhibits enkephalinase and renin-angiotensin has been developed.The first representative drug is Sacubitril Valsartan Sodium Tablet.It can delay the progression of heart failure and renal failure in patients,and can be a better choice for patients with diabetes complicated by CKD and CVD patients.Therefore,this study explores the relationship of RAAS and NP systems with CKD and CVD,and the protective effect of sacubitril valsartan on CKD and CVD with diabetes.